Human GIPR Stable Cell Line - CHO-K1

The Gastric Inhibitory Polypeptide Receptor (GIPR), alternatively designated as the glucose-dependent insulinotropic polypeptide receptor, is a thoroughly characterized Class B G protein-coupled receptor (GPCR). Biologically, GIPR is activated by its endogenous incretin peptide hormone, GIP, which is rapidly secreted by enteroendocrine K-cells in response to nutritional ingestion. Upon ligand binding, GIPR classically couples to the Gs heterotrimeric G protein complex. This interaction strongly stimulates adenylyl cyclase activity, driving a rapid intracellular accumulation of cyclic AMP (cAMP) and the subsequent activation of Protein Kinase A (PKA) signaling cascades. This specific signaling axis is fundamental to the incretin effect, acting directly to potentiate glucose-stimulated insulin secretion (GSIS) from pancreatic beta cells while concurrently regulating lipid buffering in adipocytes and modulating central neuroendocrine satiation pathways. Because of its profound role in systemic energy homeostasis, GIPR has emerged as a premier therapeutic target for Type 2 Diabetes (T2D) and the clinical management of obesity.

The Human GIPR Stable Cell Line - CHO-K1 is built upon the well-characterized Chinese hamster ovary (CHO-K1) lineage. Valued for its robust adherent growth, high metabolic stability, and remarkably low background of endogenous interfering human GPCRs, CHO-K1 serves as an optimal biological host. In standard laboratory environments, this stable in vitro model provides a highly reproducible platform for the high-throughput screening (HTS) of novel incretin-based therapeutics. This is particularly critical for the preclinical evaluation and optimization of advanced unimolecular dual-agonists (simultaneously targeting GLP-1R and GIPR) and emerging tri-agonists, which are revolutionizing the pharmacological management of severe obesity and metabolic syndrome. Because GIPR efficiently signals through the Gs/cAMP pathway, these engineered cells are perfectly optimized for highly sensitive, homogeneous cAMP accumulation assays. This allows researchers to rapidly and accurately quantify receptor activation, calculate precise half-maximal effective concentrations, and generate robust dose-response curves in real-time. Furthermore, the cell line is extensively utilized for structural pharmacological profiling, including evaluating primary ligand binding affinities, studying receptor internalization and desensitization kinetics, and characterizing allosteric modulation.